Bridging the divide between discovery and delivering patient-specific medicines is the goal of many biotech companies. Our unique approach utilises Tay Therapeutics’ technology platform coupled to in-house discovery and development expertise to deliver substantial improvements in patient care.

Squiggle Graphic
May 6, 2024
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
January 10, 2024
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
May 1, 2023
Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders